查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1268889

活生物治療產品和微生物組 CDMO 市場規模、份額、趨勢分析報告，按應用（艱難梭菌、克羅恩病、IBS、糖尿病）、按地區、按細分市場預測，2023-2030 年

Live Biotherapeutic Products And Microbiome CDMO Market Size, Share & Trends Analysis Report By Application (C.difficle, Crohns Disease, IBS, Diabetes), By Region, And Segment Forecasts, 2023 - 2030
出版日期: | 出版商: Grand View Research | 英文 120 Pages | 商品交期: 2-10個工作天內

價格

活體生物治療產品和微生物組 CDMO 的市場增長和趨勢：

Grand View Research, Inc. 的一份新報告顯示，到 2030 年的預測期內，全球活體生物治療產品和微生物組 CDMO 市場規模的複合年增長率將達到 41.3%，預計將達到 358.07 美元百萬到 2020 年。

近年來，微生物組 CDMO 和活生物治療產品 (LBP) 的市場迅速擴大，預計這一趨勢將持續下去。 患者和醫療保健提供者越來越意識到活的生物治療產品和基於微生物組的療法在治療多種疾病（包括炎症性腸病、癌症和神經系統疾病）方面的潛在益處。它是為了

致力於這些領域的 CDMO 的需求是由製藥和生物技術公司增加對活體生物治療產品和微生物藥物的投資推動的，預計這一趨勢將在未來十年持續。 隨著 LBP 和微生物衍生療法市場的擴大，公司正在尋找具有開發和製造這些產品所需技能的 CDMO。 因此，全球 CDMO 市場正在擴大，預計未來幾年將大幅擴大。 隨著這些治療開髮變得越來越複雜，外包給 CDMO 正在成為製藥和生物技術公司的一個有吸引力的選擇。

活性生物治療產品和基於微生物的療法根據用途進行市場細分，目前艱難梭菌類別在市場上占主導地位。 迫切需要有效的藥物來解決復發性艱難梭菌感染這一主要且日益嚴重的健康問題。 例如，由 Seres Therapeutics 創建的用於治療復發性艱難梭菌感染的微生物組療法 SER-109 在臨床試驗中顯示出積極的結果。 FDA 將 SER-109 歸類為突破性療法，如果獲得批准，該公司將成為艱難梭菌感染市場的重要競爭對手。 由於對有效治療艱難梭菌和其他疾病的需求不斷增長，活生物治療產品和微生物藥物市場有望發展。

COVID-19 大流行對活生物治療產品市場和微生物組合同研究與製造組織 (CDMO) 產生了重大影響。 大流行造成的中斷導致臨床試驗延遲、對某些產品的需求減少以及供應鏈中斷。 然而，隨著大流行病相關法規的放鬆以及醫療保健成為人們更加關注的焦點，預計 LBP 和基於微生物的療法市場將在未來幾年復蘇。 該領域的公司將需要適應新的挑戰並找到創新的解決方案以在大流行後的世界中維持增長。

活體生物治療產品和微生物組 CDMO 市場報告要點：

  • 艱難梭菌佔最大的收入份額，2022 年的複合年增長率最快。 艱難梭菌感染的流行率上升以及對有效治療的需求不斷增長正在推動市場增長。 許多公司都專注於開發和製造用於治療艱難梭菌感染的產品，以推動市場的擴張。
  • 北美佔據最大的市場份額，這主要是因為該地區存在主要參與者以及研發活動的投資增加。 此外，對艱難梭菌、克羅恩病和 IBS 等各種疾病的有效治療需求的增加也有助於北美市場的擴張。

內容

第一章調查方法及範圍

  • 市場細分和範圍
    • 服務
    • 最終用途
    • 估計/預測時間表
  • 調查方法
  • 信息採購
    • 購買的數據庫
    • GVR 內部數據庫
    • 次要信息
    • 初步調查
  • 信息或數據分析
    • 數據分析模型
  • 市場形成和驗證
  • 模型詳細信息
    • 產品流分析（模型 1）
    • 批量價格分析（模型 2）
  • 次要信息列表
  • 主要信息列表
  • 目的

第 2 章執行摘要

  • 市場展望

第 3 章活生物治療產品和微生物組 CDMO 市場 (CSO) 變量、趨勢和範圍

  • 市場體系展望
    • 母公司市場展望
    • 相關/補充市場展望
  • 市場動態
    • 市場驅動因素分析
    • 市場製約因素分析
      • 與外包相關的質量問題
    • COVID-19 的影響和恢復分析
    • 行業分析 - 搬運工
    • PESTLE 分析

第 4 章活生物治療產品和微生物組 CDMO 市場 (CSO)：按應用細分

  • 活生物治療產品和微生物組 CDMO 市場 (CSO) 市場：定義和範圍
  • 活生物治療產品和微生物組 CDMO 市場 (CSO) 市場：服務市場份額分析，2022 年和 2030 年
    • 艱難梭菌
      • 克羅恩病
      • 腸易激綜合徵
      • 糖尿病
      • 其他

第 5 章活生物治療產品和微生物組 CDMO 市場 (CSO)：區域分析

  • 活生物治療產品和微生物組 CDMO 市場 (CSO)：區域市場份額分析，2022 年和 2030 年
  • 北美
    • 美國
    • 加拿大
  • 歐洲
    • 英國
    • 德國
    • 法國
    • 意大利
    • 西班牙
    • 丹麥
    • 瑞典
    • 挪威
  • 亞太地區
    • 日本
    • 中國
    • 印度
    • 韓國
    • 澳大利亞
    • 泰國
  • 拉丁美洲
    • 巴西
    • 墨西哥
    • 阿根廷
  • 多邊環境協定
    • 南非
    • 沙特阿拉伯
    • 阿拉伯聯合酋長國
    • 科威特

第六章競爭格局

  • 阿蘭特簡介
    • 公司概況
    • 財務業績
    • 服務基準
    • 戰略舉措
  • 4D 製藥
    • 公司概況
    • 財務業績
    • 服務基準
    • 戰略舉措
  • 塞比奧斯
    • 公司概況
    • 財務業績
    • 服務基準
    • 戰略舉措
  • 生物產業
    • 公司概況
    • 財務業績
    • 服務基準
    • 戰略舉措
  • Assembly Biosciences, Inc.
    • 公司概況
    • 財務業績
    • 服務基準
    • 戰略舉措
  • 瓦克化學股份公司
    • 公司概況
    • 財務業績
    • 服務基準
    • 戰略舉措
  • 碼頭製藥
    • 公司概況
    • 財務業績
    • 服務基準
    • 戰略舉措
  • 尼佐
    • 公司概況
    • 財務業績
    • 服務基準
    • 戰略舉措
  • 龍沙
    • 公司概況
    • 財務業績
    • 服務基準
    • 戰略舉措
  • Inpac 益生菌
    • 公司概況
    • 財務業績
    • 服務基準
    • 戰略舉措
Product Code: GVR-4-68040-061-6

Live Biotherapeutic Products And Microbiome CDMO Market Growth & Trends:

The global live biotherapeutic products and microbiome CDMO market size is expected to reach USD 358.07 million by 2030, registering a CAGR of 41.3% over the forecast period, according to a new report by Grand View Research, Inc. The market for microbiome CDMOs and Live Biotherapeutic Products (LBPs) has been growing quickly in recent years, and this trend is anticipated to continue. the rising understanding of the potential advantages of live biotherapeutic products and microbiome-based therapeutics in treating a variety of diseases, including inflammatory bowel disease, cancer, and neurological disorders, among patients and healthcare providers.

The need for CDMOs specializing in these fields is being driven by the expanding investment by pharmaceutical and biotech businesses in live biotherapeutic products and microbiome-based medicines, and this trend is anticipated to continue in the next ten years. Companies are looking for CDMOs with the skills required to develop and produce these products as the market for LBPs and microbiome-based therapeutics grows.This has resulted in the growth of the global CDMO market, with significant expansion expected in the coming years. Outsourcing to CDMOs is becoming an attractive option for pharmaceutical and biotech companies due to the increasing complexity of developing these therapies.

Applications-based market segments have been created for live biotherapeutic products and microbiome-based therapeutics, with the C. difficile category currently dominating the market. Effective medicines are desperately required to tackle the major and expanding health issue of recurrent C. difficile infection. For instance, SER-109, a microbiome therapy created by Seres Therapeutics for the treatment of recurrent C. difficile infection, has demonstrated good outcomes in clinical trials. The FDA has given the business SER-109's breakthrough therapy classification; if approved, this would position the company as a significant contender in the market for C. difficile medicines. The market for live biotherapeutic products and microbiome-based medicines is anticipated to develop since there is an increasing need for effective treatments for C. difficile and other illnesses.

The COVID-19 pandemic has had a significant impact on the market for live biotherapeutic products and microbiome Contract Development and Manufacturing Organizations (CDMOs). The disruption caused by the pandemic has led to delays in clinical trials, decreased demand for certain products, and supply chain disruptions. However, with the easing of pandemic-related restrictions and the increasing focus on healthcare, the market for LBPs and microbiome-based therapies is expected to rebound in the coming years. Companies in this space will need to adapt to new challenges and find innovative solutions to maintain growth in a post-pandemic world.

Live Biotherapeutic Products And Microbiome CDMO Market Report Highlights:

  • C.difficle holds the largest revenue share and fastest CAGR in 2022. The increasing prevalence of C.difficle infections and the growing demand for effective treatments are propelling the growth of the market. Many companies are focusing on developing and manufacturing products for the treatment of C.difficle infections, driving the market's expansion
  • North America has dominated the market with the largest market share, primarily due to the presence of key players and increasing investments in research and development activities in this region. The growing demand for effective treatments for various diseases such as C.difficile, Crohn's disease, and IBS, has also contributed to the market growth in North America

Table of Content

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation & Scope
    • 1.1.1. Service
    • 1.1.2. End use
    • 1.1.3. Estimates and forecast timeline
  • 1.2. Research Methodology
  • 1.3. Information Procurement
    • 1.3.1. Purchased database
    • 1.3.2. GVR's internal database
    • 1.3.3. Secondary sources
    • 1.3.4. Primary research
  • 1.4. Information or Data Analysis
    • 1.4.1. Data analysis models
  • 1.5. Market Formulation & Validation
  • 1.6. Model Details
    • 1.6.1. Commodity flow analysis (Model 1)
    • 1.6.2. Volume price analysis (Model 2)
  • 1.7. List of Secondary Sources
  • 1.8. List of Primary Sources
  • 1.9. Objectives
    • 1.9.1. Objective 1
    • 1.9.2. Objective 2
    • 1.9.3. Objective 3
    • 1.9.4. Objective 4

Chapter 2. Executive Summary

  • 2.1. Market Outlook

Chapter 3. Live Biotherapeutic Products and Microbiome CDMO Market (CSO) Variables, Trends & Scope

  • 3.1. Market Lineage Outlook
    • 3.1.1. Parent market outlook
    • 3.1.2. Related/ancillary market outlook
  • 3.2. Market Dynamics
    • 3.2.1. Market driver analysis
    • 3.2.2. Market restraint analysis
      • 3.2.2.1. Quality issues associated with outsourcing
    • 3.2.3. Covid-19 Impact & Recovery Analysis
    • 3.2.4. Industry Analysis - Porter's
    • 3.2.5. PESTLE Analysis

Chapter 4. Live Biotherapeutic Products and Microbiome CDMO Market (CSO): Application Segment Analysis

  • 4.1. Live Biotherapeutic Products and Microbiome CDMO Market (CSO) Market : Definition & Scope
  • 4.2. Live Biotherapeutic Products and Microbiome CDMO Market (CSO) Market : Service Market Share Analysis, 2022 & 2030
    • 4.2.1. C.difficle
      • 4.2.1.1. C.difficle market, 2018 - 2030 (USD Million)
      • 4.2.1.2. Crohns disease
      • 4.2.1.2.1. Crohns disease market, 2018 - 2030 (USD Million)
      • 4.2.1.3. IBS
      • 4.2.1.3.1. IBS market, 2018 - 2030 (USD Million)
      • 4.2.1.4. Diabetes
      • 4.2.1.4.1. Diabetes market, 2018 - 2030 (USD Million)
      • 4.2.1.5. Others
      • 4.2.1.5.1. Others market, 2018 - 2030 (USD Million)

Chapter 5. Live Biotherapeutic Products and Microbiome CDMO Market (CSO): Regional Analysis

  • 5.1. Live Biotherapeutic Products and Microbiome CDMO Market (CSO): Regional market share analysis, 2022 & 2030
  • 5.2. North America
    • 5.2.1. North America Market estimates and forecast, 2018 - 2030
    • 5.2.2. U.S.
      • 5.2.2.1. U.S. Market estimates and forecast, 2018 - 2030
    • 5.2.3. Canada
      • 5.2.3.1. Canada Market estimates and forecast, 2018 - 2030
  • 5.3. Europe
    • 5.3.1. Europe Market estimates and forecast, 2018 - 2030
    • 5.3.2. UK
      • 5.3.2.1. UK Market estimates and forecast, 2018 - 2030
    • 5.3.3. Germany
      • 5.3.3.1. Germany Market estimates and forecast, 2018 - 2030
    • 5.3.4. France
      • 5.3.4.1. France Market estimates and forecast, 2018 - 2030
    • 5.3.5. Italy
      • 5.3.5.1. Italy Market estimates and forecast, 2018 - 2030
    • 5.3.6. Spain
      • 5.3.6.1. Spain Market estimates and forecast, 2018 - 2030
    • 5.3.7. Denmark
      • 5.3.7.1. Denmark Market estimates and forecast, 2018 - 2030
    • 5.3.8. Sweden
      • 5.3.8.1. Sweden Market estimates and forecast, 2018 - 2030
    • 5.3.9. Norway
      • 5.3.9.1. Norway Market estimates and forecast, 2018 - 2030
  • 5.4. Asia Pacific
    • 5.4.1. Asia Pacific Market estimates and forecast, 2018 - 2030
    • 5.4.2. Japan
      • 5.4.2.1. Japan Market estimates and forecast, 2018 - 2030
    • 5.4.3. China
      • 5.4.3.1. China Market estimates and forecast, 2018 - 2030
    • 5.4.4. India
      • 5.4.4.1. India Market estimates and forecast, 2018 - 2030
    • 5.4.5. South Korea
      • 5.4.5.1. South Korea Market estimates and forecast, 2018 - 2030
    • 5.4.6. Australia
      • 5.4.6.1. Australia Market estimates and forecast, 2018 - 2030
    • 5.4.7. Thailand
      • 5.4.7.1. Thailand Market estimates and forecast, 2018 - 2030
  • 5.5. Latin America
    • 5.5.1. Latin America Market estimates and forecast, 2018 - 2030
    • 5.5.2. Brazil
      • 5.5.2.1. Brazil Market estimates and forecast, 2018 - 2030
    • 5.5.3. Mexico
      • 5.5.3.1. Mexico Market estimates and forecast, 2018 - 2030
    • 5.5.4. Argentina
      • 5.5.4.1. Argentina Market estimates and forecast, 2018 - 2030
  • 5.6. `MEA
    • 5.6.1. MEA Market estimates and forecast, 2018 - 2030
    • 5.6.2. South Africa
      • 5.6.2.1. South Africa Market estimates and forecast, 2018 - 2030
    • 5.6.3. Saudi Arabia
      • 5.6.3.1. Saudi Arabia Market estimates and forecast, 2018 - 2030
    • 5.6.4. UAE
      • 5.6.4.1. UAE Market estimates and forecast, 2018 - 2030
    • 5.6.5. Kuwait
      • 5.6.5.1. Kuwait Market estimates and forecast, 2018 - 2030

Chapter 6. Competitive Landscape

  • 6.1. Arrant Bio
    • 6.1.1. Company overview
    • 6.1.2. Financial performance
    • 6.1.3. Service benchmarking
    • 6.1.4. Strategic initiatives
  • 6.2. 4D Pharma
    • 6.2.1. Company overview
    • 6.2.2. Financial performance
    • 6.2.3. Service benchmarking
    • 6.2.4. Strategic initiatives
  • 6.3. Cerbios
    • 6.3.1. Company overview
    • 6.3.2. Financial performance
    • 6.3.3. Service benchmarking
    • 6.3.4. Strategic initiatives
  • 6.4. Biose Industrie
    • 6.4.1. Company overview
    • 6.4.2. Financial performance
    • 6.4.3. Service benchmarking
    • 6.4.4. Strategic initiatives
  • 6.5. Assembly Biosciences, Inc
    • 6.5.1. Company overview
    • 6.5.2. Financial performance
    • 6.5.3. Service benchmarking
    • 6.5.4. Strategic initiatives
  • 6.6. Wacker Chemie AG
    • 6.6.1. Company overview
    • 6.6.2. Financial performance
    • 6.6.3. Service benchmarking
    • 6.6.4. Strategic initiatives
  • 6.7. Quay Pharmaceuticals
    • 6.7.1. Company overview
    • 6.7.2. Financial performance
    • 6.7.3. Service benchmarking
    • 6.7.4. Strategic initiatives
  • 6.8. NIZO
    • 6.8.1. Company overview
    • 6.8.2. Financial performance
    • 6.8.3. Service benchmarking
    • 6.8.4. Strategic initiatives
  • 6.9. LONZA
    • 6.9.1. Company overview
    • 6.9.2. Financial performance
    • 6.9.3. Service benchmarking
    • 6.9.4. Strategic initiatives
  • 6.10. Inpac Probiotics
    • 6.10.1. Company overview
    • 6.10.2. Financial performance
    • 6.10.3. Service benchmarking
    • 6.10.4. Strategic initiatives

List of Tables

  • TABLE 1 List of secondary sources
  • TABLE 2 List of Abbreviations

List of Figures

  • FIG. 1 Market research process
  • FIG. 2 Information Procurement
  • FIG. 3 Primary research pattern
  • FIG. 4 Market research approaches
  • FIG. 5 Value chain based sizing & forecasting
  • FIG. 6 QFD modelling for market share assessment
  • FIG. 7 Market segmentation & scope
  • FIG. 8 Live Biotherapeutic Products and Microbiome CDMO outlook, 2018 - 2030
  • FIG. 9 Market trends & outlook
  • FIG. 10 Market driver relevance analysis (Current & future impact)
  • FIG. 11 Market restraint relevance analysis (Current & future impact)
  • FIG. 12 SWOT Analysis, By Factor (political & legal, economic and technological)
  • FIG. 13 Porter's Five Forces Analysis
  • FIG. 14 Live Biotherapeutic Products and Microbiome CDMO : Application outlook key takeaways
  • FIG. 15 Live Biotherapeutic Products and Microbiome CDMO : Application movement analysis
  • FIG. 16 C.difficle market, 2018 - 2030 (USD Million)
  • FIG. 17 Crohns disease market, 2018 - 2030 (USD Million)
  • FIG. 18 IBS market, 2018 - 2030 (USD Million)
  • FIG. 19 Diabetes market, 2018 - 2030 (USD Million)
  • FIG. 20 Others market, 2018 - 2030 (USD Million)
  • FIG. 21 Regional market place: Key takeaway
  • FIG. 22 Live Biotherapeutic Products and Microbiome CDMO regional outlook, 2020 & 2028
  • FIG. 23 North America Live Biotherapeutic Products and Microbiome CDMO market, 2018 - 2030 (USD Million)
  • FIG. 24 U.S. Live Biotherapeutic Products and Microbiome CDMO market, 2018 - 2030 (USD Million)
  • FIG. 25 Canada Live Biotherapeutic Products and Microbiome CDMO market, 2018 - 2030 (USD Million)
  • FIG. 26 Europe Live Biotherapeutic Products and Microbiome CDMO market, 2018 - 2030 (USD Million)
  • FIG. 27 Germany Live Biotherapeutic Products and Microbiome CDMO market, 2018 - 2030 (USD Million)
  • FIG. 28 France Live Biotherapeutic Products and Microbiome CDMO market, 2018 - 2030 (USD Million)
  • FIG. 29 UK Live Biotherapeutic Products and Microbiome CDMO market, 2018 - 2030 (USD Million)
  • FIG. 30 Spain Live Biotherapeutic Products and Microbiome CDMO market, 2018 - 2030 (USD Million)
  • FIG. 31 Italy Live Biotherapeutic Products and Microbiome CDMO market, 2018 - 2030 (USD Million)
  • FIG. 32 Denmark Live Biotherapeutic Products and Microbiome CDMO market, 2018 - 2030 (USD Million)
  • FIG. 33 Sweden Live Biotherapeutic Products and Microbiome CDMO market, 2018 - 2030 (USD Million)
  • FIG. 34 Norway Live Biotherapeutic Products and Microbiome CDMO market, 2018 - 2030 (USD Million)
  • FIG. 35 Asia Pacific Live Biotherapeutic Products and Microbiome CDMO market, 2018 - 2030 (USD Million)
  • FIG. 36 China Live Biotherapeutic Products and Microbiome CDMO market, 2018 - 2030 (USD Million)
  • FIG. 37 Japan Live Biotherapeutic Products and Microbiome CDMO market, 2018 - 2030 (USD Million)
  • FIG. 38 India Live Biotherapeutic Products and Microbiome CDMO market, 2018 - 2030 (USD Million)
  • FIG. 39 Thailand Live Biotherapeutic Products and Microbiome CDMO market, 2018 - 2030 (USD Million)
  • FIG. 40 South Korea Live Biotherapeutic Products and Microbiome CDMO market, 2018 - 2030 (USD Million)
  • FIG. 41 Australia Live Biotherapeutic Products and Microbiome CDMO market, 2018 - 2030 (USD Million)
  • FIG. 42 Latin America Live Biotherapeutic Products and Microbiome CDMO market, 2018 - 2030 (USD Million)
  • FIG. 43 Brazil Live Biotherapeutic Products and Microbiome CDMO market, 2018 - 2030 (USD Million)
  • FIG. 44 Mexico Live Biotherapeutic Products and Microbiome CDMO market, 2018 - 2030 (USD Million)
  • FIG. 45 Argentina Live Biotherapeutic Products and Microbiome CDMO market, 2018 - 2030 (USD Million)
  • FIG. 46 Middle East & Africa Live Biotherapeutic Products and Microbiome CDMO market, 2018 - 2030 (USD Million)
  • FIG. 47 South Africa Live Biotherapeutic Products and Microbiome CDMO market, 2018 - 2030 (USD Million)
  • FIG. 48 Saudi Arabia Live Biotherapeutic Products and Microbiome CDMO market, 2018 - 2030 (USD Million)
  • FIG. 49 UAE Live Biotherapeutic Products and Microbiome CDMO market, 2018 - 2030 (USD Million)
  • FIG. 50 Kuwait Live Biotherapeutic Products and Microbiome CDMO market, 2018 - 2030 (USD Million)